截至目前，古彪先生未持有公司股份，不存在应当履行而未履行的承诺事项。 公司董事会对古彪先生担任公司内部审计负责人期间为公司发展和内部审计工 作所做的贡献表示衷心的感谢。 广东嘉应制药股份有限公司 关于变更公司内部审计负责人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开 第七届董事会第八次临时会议，审议通过了《关于变更公司内部审计负责人的议 案》，现将有关情况公告如下： 公司董事会近日收到公司内部审计负责人古彪先生的书面辞职报告，其因个 人原因申请辞去公司内部审计负责人职务，辞职后古彪先生不再公司担任其他任 何职务。根据相关规定，该辞职报告自送达公司董事会之日起生效。 二、内部审计负责人聘任情况 为保证公司内部审计工作的正常开展，根据《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 《公司章程》的相关规定，经公司董事会审计委员会提名、董事会提名委员会审 核，公司同意聘任蒋坤女士为公司内部审计负责人，任职期限自本次董事 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002198 证券简称：嘉应制药 公告编号：2025-037 广东嘉应制药股份有限公司 关于聘任公司证券事务代表的公告 附件：曹科骏简历 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开 第七届董事会第八次临时会议，审议通过了《关于聘任公司证券事务代表的议案》， 现将有关情况公告如下： 经公司总经理游永平先生提名，董事会提名委员会审查，公司同意聘任曹科 骏先生为公司证券事务代表，协助董事会秘书履行信息披露及维护投资者关系等 职责，任职期限自本次董事会审议通过之日起至第七届董事会届满之日止。曹科 骏先生已参加最近一期董事会秘书培训并承诺取得深圳证券交易所认可的董事 会秘书培训证明。 公司证券事务代表联系方式如下： 2、传真：0753-2321586 3、邮箱：jyzy_gd@163.com 4、地址：湖南省长沙市高新开发区麓谷工业园林语路 36 号 曹科骏简历详见附件。 特此公告。 广东嘉应制药股份有限公司董事会 2025年6月28日 1、电话：0753-2321916 ...

第七届董事会第八次临时会议决议公告 一、董事会会议召开情况 1、广东嘉应制药股份有限公司（以下简称"公司"）第七届董事会第八次临 时会议通知已于 2025 年 6 月 24 日以电子邮件及通讯等方式送达公司全体董事、 高级管理人员及监事。 2、2025 年 6 月 27 日，会议在嘉应制药（湖南）有限公司会议室以现场结 合通讯方式举行。会议应出席董事 9 人，实际出席董事 9 人，其中委托出席的董 事 0 人，以通讯表决方式出席的董事有曹邦俊、游永平、姚远、戴儒荣、郭华平、 徐驰、李善伟、李俊国。公司部分高级管理人员、监事列席了会议，会议由董事 长李能先生主持。本次会议的召集、召开符合法律、法规及公司章程的规定，表 决形成的决议合法、有效。 二、董事会会议审议情况 经与会董事认真审议并表决，形成如下决议： 证券代码：002198 证券简称：嘉应制药 公告编号：2025-035 广东嘉应制药股份有限公司 第七届董事会第八次临时会议决议公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚 假记载、误导性陈述或者重大遗漏。 1、审议通过《关于聘任公司财务负责人的议案》 表决结果为：9 票同意，0 ...

Group 1 - The core viewpoint of the articles highlights that Jia Ying Pharmaceutical is currently under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact investor confidence and stock performance [2][3] - As of June 20, 2023, Jia Ying Pharmaceutical's financing balance is 248 million yuan, representing 8.17% of its market capitalization, which is below the historical 50th percentile level [2] - The company reported a significant decline in financial performance for 2024, with total operating revenue of 376 million yuan, down 29.46% year-on-year, and a net profit attributable to shareholders of 21 million yuan, down 39.94% year-on-year [3] Group 2 - Investors who purchased Jia Ying Pharmaceutical shares between its listing and May 28, 2025, and still held them at the close on that date, may be eligible for compensation due to the company's alleged information disclosure failures [3] - The company, established in 2003 and a member of the Sheneng Group, is primarily engaged in the pharmaceutical manufacturing industry, specifically in traditional Chinese medicine [3]

Group 1 - The core issue revolves around the investigation into Jia Ying Pharmaceutical for disclosure violations, particularly regarding significant fund transfers to related parties without board approval, which raises concerns about governance and internal controls [1] - In the fourth quarter of 2024, the company engaged in undisclosed related party transactions amounting to 10.39 million yuan with its second-largest shareholder, highlighting a lack of transparency [1] - The independent director's misconduct, including undisclosed shareholdings and illegal stock sales, further illustrates governance failures within the company [1] Group 2 - Despite a revenue increase of 28.83% and a net profit surge of 197.23% in Q1 2025, the company faces long-term structural challenges due to a significant revenue drop of 29.46% in 2024, primarily driven by price cuts in core products [2] - The company's cash flow deteriorated sharply, with a net operating cash flow of -11.83 million yuan in Q1 2025, indicating a decline in profitability quality [2] - Research and development expenditures fell to a record low of 6.76 million yuan in 2024, representing only 1.8% of revenue, which is concerning given the company's reliance on a single product line [2]

Core Viewpoint - The investigation by the China Securities Regulatory Commission (CSRC) into Jiaying Pharmaceutical highlights severe governance issues within the company, exacerbated by a significant decline in revenue from its core products and ongoing management turmoil [2][3][15]. Governance and Management Issues - Jiaying Pharmaceutical is under investigation for information disclosure violations, which are seen as a culmination of long-standing governance deficiencies [3][15]. - The company has experienced a rapid turnover of key executives, including the resignation of the financial director and board secretary, raising concerns about internal governance stability [4][5]. - A lack of timely disclosure regarding related party transactions and internal control weaknesses has been identified as potential triggers for the investigation [3][5]. Financial Performance - Jiaying Pharmaceutical reported a revenue of 376.17 million yuan in 2024, a decrease of 29.46% year-on-year, marking two consecutive years of double-digit declines [6][7]. - The net profit attributable to shareholders fell to 20.61 million yuan, down 39.94% from the previous year, with a net profit margin dropping from 6.44% in 2023 to 5.48% in 2024 [6][7]. - The company's core products, particularly the Jieguzhili Pian/Capsule, saw a revenue decline of 41.05%, significantly impacting overall performance [9][10]. Market and Product Dynamics - The ongoing pressure from national traditional Chinese medicine procurement policies has led to a dual impact of declining prices and sales volumes for Jiaying Pharmaceutical's key products [9][10]. - The company’s revenue structure is imbalanced, with major products underperforming and insufficient growth from secondary products, leading to a "main force slowdown, new force insufficiency" scenario [9][10]. Research and Development Concerns - Jiaying Pharmaceutical's R&D expenditure decreased by 33.09% in 2024, raising concerns about its long-term competitiveness and innovation capabilities [14][15]. - The reduction in R&D personnel from 42 to 30 indicates a shrinking focus on innovation, which is critical in the increasingly competitive pharmaceutical industry [14][15]. Recent Developments - In the first quarter of 2025, Jiaying Pharmaceutical reported a revenue increase of 28.83% year-on-year, attributed to expanded sales channels, although this was not accompanied by improved cash flow [11][12]. - Despite a temporary recovery in performance, the ongoing decline in R&D investment poses risks to the company's future growth and sustainability [14][15].

关于股份回购进展情况的公告 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 一、回购方案的主要内容 广东嘉应制药股份有限公司（以下简称"公司"）于2024年12月12日召开的第 七届董事会第四次临时会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金以集中竞价方式回购部分公司已发行的人民币普通股（A股） 股票，回购的股份将用于实施员工持股计划或股权激励，本次拟回购股份数量为 不少于700万股（含），且不超过1,350万股（含），按照回购股份数量上限1,350 万股（含）、回购股份价格上限9.80元/股（含）测算，回购股份的总金额不超过 13,230.00万元（含），具体回购股份的金额以回购实施完成时实际回购使用的金 额为准。本次回购的实施期限为自公司董事会审议通过本次回购股份方案之日起 12个月内。详见公司于2024年12月14日在《证券时报》《中国证券报》《证券日 报》及巨潮资讯网（www.cninfo.com.cn）上披露的《第七届董事会第四次临时会 议决议公告》（公告编号：2024-050）及《广东嘉应制药股份有限公司关于回购 公司股份方案的 ...

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, leading to significant stock price declines and market capitalization loss [1][3]. Financial Performance - As of December 31, 2024, the company reported revenue of 376 million yuan, a year-on-year decrease of 29.46%, and a net profit attributable to shareholders of 20.61 million yuan, down 39.94% year-on-year [4]. Internal Control Issues - The investigation was triggered by major internal control deficiencies, highlighted in the company's self-evaluation report, which received a qualified opinion from Zhonghua Accounting Firm [6]. - From September 2024 to January 2025, Jiaying Pharmaceutical's wholly-owned subsidiary transferred a total of 170 million yuan to related party Hunan Yaojuneng Pharmaceutical Co., Ltd. without board approval, using a "beginning of month transfer, end of month return" method to obscure the transactions [6]. - In the fourth quarter of 2024, the company engaged in related party transactions totaling 10.39 million yuan with its second-largest shareholder and other related parties, failing to follow proper board review and disclosure procedures [6].

Core Viewpoint - The company, Jiaying Pharmaceutical, is facing significant governance and compliance issues, including violations of information disclosure regulations and internal control deficiencies, which have led to regulatory scrutiny and potential legal consequences [1][2][5]. Group 1: Information Disclosure Violations - Jiaying Pharmaceutical has been found to have concealed related party transactions and fund misappropriation, with transactions totaling 10.39 million yuan that were not submitted for board approval or timely disclosed [2]. - From September 2024 to January 2025, the company's subsidiary transferred 235 million yuan to related parties without board approval, violating corporate governance laws [2]. Group 2: Governance Crisis - A wave of resignations among key management personnel, including the board secretary and CFO, has raised concerns about the stability of the company's governance structure [3]. - The second largest shareholder, Yangtianhe, acquired a 7% stake in Jiaying Pharmaceutical for 355 million yuan but subsequently pledged all shares, indicating financial pressure and potential conflicts of interest [3]. Group 3: Financial Performance Concerns - In 2024, the company's revenue declined by 29.46%, with a 41.05% drop in sales of its main product, indicating weakening market competitiveness [4]. - Despite a 197.23% increase in net profit in Q1 2025, the company's operating cash flow turned negative, raising concerns about the quality of earnings and potential revenue recognition issues [4]. Group 4: Regulatory and Investor Impact - The accounting firm issued a report highlighting the company's internal control and disclosure deficiencies, which could lead to penalties, market bans, or even delisting if violations are confirmed [5]. - Legal actions for investor compensation have been initiated, with potential claims for losses incurred by investors who bought shares before May 28, 2025, and sold or held them after [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 来源：@证券市场周刊微博 日前，嘉应制药（维权）（002198.SZ）发布公告，公司因涉嫌信息披露违法违规被中国证监会立案。 这已不是公司第一次受到监管部门处罚。此前在2021年10月、2022年6月公司曾因信息披露违规分别收到中国证监 会和广东证监局的警示函。 公告编号:2025-033 广东嘉应制药股份有限公司 关于收到中国证券监督管理委员会立案告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 颇为巧合的是，就在公司一季报发布不久的2025年5月20日，公司又发布了财务总监辞职的公告。而截至2025年5月 20日，公司有股东24009户。 此次嘉应制药被立案，如果证监会经过调查，最终对公司实施行政处罚，根据相关司法解释，在2025年5月28日收 盘之前买入公司股票，且在2025年5月28日后卖出或仍持有并曾产生一定浮亏（无论是否解套）的投资者，可通过 法律途径维护自身合法权益，最终索赔条件与获赔金额将以法院认定为准。 相关事宜可关注《证券市场周刊》微信公众号（ID：capitalweek），点击 ...